Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH): Oseltamivir Phosphate oral suspension obtains drug registration certificate.

25/09/2024

GMT Eight

Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH) announced that the company recently received the "Drug Registration Certificate" for the phosphoric acid oseltamivir suspension issued by the National Medical Products Administration (referred to as "NMPA") (certificate number: 2024S02238). It is reported that the phosphoric acid oseltamivir suspension is an anti-influenza virus drug, mainly used for the treatment of influenza A and B in patients aged 2 weeks and above, as well as for the prevention of influenza A and B in individuals aged 1 year and above.

HuiZhou Intelligence Technology Group (002122.SZ) plans to participate in the investment in Lingben Focused Investment Fund, which specializes in investing in LightChi Semiconductor.

The Securities and Futures Commission of Hong Kong: Hong Kong's securities industry net profit was HK$19 billion in the first half of the year, an increase of 29% year-on-year.

Contact: contact@gmteight.com

Jiangsu Sinopep-Allsino Biopharmaceutical (688076.SH): Oseltamivir Phosphate oral suspension obtains drug registration certificate.

RECOMMEND

Shanxi Coking Coal Energy Group's subsidiary Jining Coal Industry resumes production.

Jiangxi Sanxin Medtec (300453.SZ) plans to invest approximately 500 million yuan in the construction of a new project industrializing high-performance blood purification equipment and supporting consumables.

Founder (601901.SH) plans to distribute a dividend of 0.048 yuan per share for the first half of the year, with the ex-dividend and ex-rights date set for October 11th.